Serum Institute of India begins production of Covovax vaccine
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
SUNDAY, MAY 29, 2022
SUNDAY, MAY 29, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
Serum Institute of India begins production of Covovax vaccine

Coronavirus chronicle

Hindustan Times
27 May, 2021, 11:00 am
Last modified: 27 May, 2021, 11:28 am

Related News

  • India's Serum Institute applies for full approval of Covishield vaccine
  • India's Serum plans to launch Novavax shot for children in six months
  • 2.5M AstraZeneca vaccine doses arrive in Dhaka
  • Serum may resume vaccine export in July/August
  • Serum can supply 6 lakh Covishield to Sri Lanka if purchased for $15 per dose

Serum Institute of India begins production of Covovax vaccine

US biotechnology company Novavax’s protein-based Covid-19 vaccine, NVX-CoV2373, is being locally manufactured by SII under the brand name Covovax

Hindustan Times
27 May, 2021, 11:00 am
Last modified: 27 May, 2021, 11:28 am
The company is already locally producing the Covishield vaccine developed by Oxford University and AstraZeneca. Photo: AP via Hindustan Times
The company is already locally producing the Covishield vaccine developed by Oxford University and AstraZeneca. Photo: AP via Hindustan Times

The Serum Institute of India (SII) has begun at risk production of its second Covid-19 vaccine, Covovax, in India, according to people familiar with the development.

US biotechnology company Novavax's protein-based Covid-19 vaccine, NVX-CoV2373, is being locally manufactured by SII under the brand name Covovax.

The company is already locally producing the Covishield vaccine developed by Oxford University and AstraZeneca.

"The numbers obviously cannot be disclosed but the manufacturing and stockpiling has already begun like it happened for the Oxford-AstraZeneca vaccine last year; in a small way though," a person at the industry said on condition of anonymity.

The development, however, was not confirmed by the Union health ministry or the national drugs controller's office.

Besides the Covishield vaccine, SII is also committed to sharing Covovax doses with the COVAX facility to be distributed among low and middle income countries.

In an interview to CNBC-TV18 last month, SII chief executive officer Adar Poonawalla said that they planned to begin stockpiling soon even though manufacturing was impacted somewhat because of curbs that the US had earlier put on export of raw materials.

"…we are starting to stockpile and manufacture Covovax this month itself… Right now, we could have been making twice as much if we had the raw materials; having said that, in the next four to five months, we would have made adequate arrangements from other suppliers outside of the US which is good news, so this is only a temporary problem. We just need it for these three months; after that we will be completely self-reliant," he said.

In March, Poonawalla had informed that Covovax clinical trials had begun in India.

Covovax, however, has not received regulatory clearance anywhere so far.

"After Novavax gets approvals abroad with efficacy trials, then we can look at maybe launching it in India. Having said that, I still want to complete my trials in India for Covovax to be absolutely sure that this product we made is identical to Novavax, and we want to adhere to those standards before we launch the product in India, so it's going to take two-three months. But the good news is that if we can start stockpiling enough quantities, it won't matter because in three or four months, we can then give those doses to India, and other parts of the world. The key issue is that we are going to establish that the quality of the product that we are making and stockpiling here is identical to standard quality compared to Novavax, and that's going to take a couple of months," he added.

Top News / World+Biz

Serum / Covovax vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Finance projects export fall, remittance rise
    Finance projects export fall, remittance rise
  • Photo: TBS
    After 72-hour ultimatum, health directorate goes after illegal medical facilities 
  • Photo: Bloomberg
    Direct shipping now to Netherlands 

MOST VIEWED

  • People wearing protective face masks walk on a street, following new cases of the coronavirus disease (Covid-19), in Shanghai, China August 25, 2021. REUTERS/Aly Song
    'Tomorrow will be better': Shanghai inches towards Covid re-opening
  • North Korea says new fever cases under 100,000 as virus fight heats up
    North Korea says new fever cases under 100,000 as virus fight heats up
  • People in protective suits cross a street during lockdown, amid the coronavirus disease (COVID-19) pandemic, in Shanghai, China, May 26, 2022. REUTERS/Aly Song
    Shanghai heading out of lockdown but China still lost in economic gloom
  • A woman wearing a face mask crosses a road at the Central Business District (CBD), amid the coronavirus disease (Covid-19) outbreak in Beijing, China May 10, 2022. REUTERS/Carlos Garcia Rawlins
    Tightening Covid net, Beijing deals out punishments, stark warnings
  • A medical worker takes a swab sample from a person for a nucleic acid test at a makeshift testing site, amid the coronavirus disease (Covid-19) outbreak, in Beijing, China May 23, 2022. REUTERS/Tingshu Wang
    Beijing ramps up Covid quarantine, Shanghai residents decry uneven rules
  • A vial labelled with the Pfizer-BioNTech coronavirus disease (Covid-19) vaccine is seen in this illustration picture taken March 19, 2021. Photo :Reuters
    Pfizer says 3 Covid shots protect children under 5

Related News

  • India's Serum Institute applies for full approval of Covishield vaccine
  • India's Serum plans to launch Novavax shot for children in six months
  • 2.5M AstraZeneca vaccine doses arrive in Dhaka
  • Serum may resume vaccine export in July/August
  • Serum can supply 6 lakh Covishield to Sri Lanka if purchased for $15 per dose

Features

Women voluntarily joined the peaceful procession and protested by wearing clothing of their own choice. Photo: Trishia Nashtaran

The unhealthy obsession with what women wear

1h | Panorama
Illustration: Freepik

Bangladesh is on the verge of destigmatising menstruation

5h | Features
Photo: Collected

The death of Davos?

11h | Panorama
A male Baya Weaver beating wings. Photo: Enam Ul Haque

Baya Weavers weave: ‘Must be witnessed to be fully credited’

15h | Panorama

More Videos from TBS

Attorney General's suggestion to reduce case clutter

Attorney General's suggestion to reduce case clutter

6h | Videos
Russian forces take Liman city of Ukraine

Russian forces take Liman city of Ukraine

6h | Videos
JU food prices spike, students suffer

JU food prices spike, students suffer

6h | Videos
5% tax on poultry farmers earning above Tk10 lakh

5% tax on poultry farmers earning above Tk10 lakh

6h | Videos

Most Read

1
Bangladesh Bank GM, DGM’s designation changed
Banking

Bangladesh Bank GM, DGM’s designation changed

2
Corporates go cashless…tax cut on cards
NBR

Corporates go cashless…tax cut on cards

3
Photo: Courtesy
Panorama

Misfit Technologies: A Singaporean startup rooted firmly in Bangladesh

4
British International Investment (BII) CEO Nick O’Donohoe. Illustration: TBS
Economy

BII to invest $450m in Bangladesh in 5 years

5
Representational image. Picture: Pixabay
Economy

Govt raises regulatory duty to discourage imports of 130 products

6
Photo: Collected
Industry

Spanish recycled cotton producer opens new facility in Bangladesh

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab